Human rotavirus vaccine and preparation method thereof

Abstract

The invention discloses a human rotavirus vaccine. The human rotavirus vaccine is a combined vaccine which is formed by polyvalent pneumococcal polysaccharide and two or more than two of carrier proteins by virtue of connectors, wherein the connectors are magnetic nano-microspheres; one of the carrier proteins is a rotavirus protein. A preparation method of the human rotavirus vaccine comprises a step of respectively coupling the polyvalent pneumococcal polysaccharide and two or more than two of carrier proteins (one of the carrier proteins is the rotavirus protein) with the magnetic nano-microspheres. The human rotavirus vaccine is simple in preparation process; by adopting the human rotavirus vaccine using the nano-microspheres as the connector, the mice Th1-type immune response, and the immune persistence, specificity and affinity of the polysaccharide specific antibody can be increased; in addition, the mice can be induced so as to produce rotavirus antibodies; the human rotavirus vaccine has the prevention effect of two vaccines; therefore, the human rotavirus vaccine has very wide application prospect.

Description

technical field [0001] The invention relates to a vaccine, in particular to a human rotavirus vaccine and a preparation method thereof, belonging to the field of biotechnology. Background technique [0002] 1. The harm of microorganisms to the human body and countermeasures [0003] Microorganisms usually refer to those biological groups whose individual volume diameter is generally less than 1mm. They have a simple structure, most of which are single cells, and some do not even have a cell structure. To clarify their morphology and structure; Among them, pathogenic microorganisms refer to pathogenic microorganisms that can cause diseases of humans, animals and plants. The pathogenicity of a pathogen depends on its ability to invade the host and reproduce in vivo and resist host resistance without being eliminated by it. The pathogenicity of microorganisms has species characteristics, and the degree of pathogenicity is called virulence. The establishment of infectious dis...

AI Technical Summary

Problems solved by technology

But this kind of polysaccharide vaccine has the following problems: (1) in young animals or infants, only weak immune response can be produced, or even no immune response, and the immune response will increase with age; (2) produce low-affinity antibodies (3) only produce short-lived immune response, do not have immune memory and immune enhancement effect during repeated vaccination; (4) easy to produce immune tolerance; (5) common adjuvant is not easy to play the role of immune enhancement to this antigen Effect, the 23-valent polysaccharide vaccine has a protection rate of 50-70% for invasive pulmonary chain infection, and can only be used for vaccination of people over 2 years old, while the peak age of onset of pneumonia is 6-12 months old; (6) has Polysaccharides with repeating structures are T cell-independent type 2 immunogens. Without the participation of T cells, they cannot induce immune memory effects, and the antibodies that stimulate the body are mainly IgM and IgG2, which cannot effectively activate the complement system

[0021] However, the above-mentioned traditional polysaccha

Images